Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Positive Results in Phase 3 Inavir Trial

By Drug Discovery Trends Editor | August 22, 2012

Daiichi Sankyo Company Ltd. announced that the influenza antiviral product Inavir dry powder inhaler  (laninamivir octanoate hydrate) significantly reduced the incidence of influenza infection compared to placebo in a Phase 3 clinical study. Based on these results, Daiichi Sankyo intends to seek approval for a prophylaxis indication for Inavir.

The objective of the study was to investigate the efficacy in the prevention of influenza virus infection among household contacts of patients with influenza A or B virus infection. In a placebo-controlled, randomized, double-blind study, the prophylactic efficacy of Inavir was examined against influenza infection. Inavir statistically significantly reduced the incidence of the clinical influenza virus infection among household contacts, the primary endpoint of efficacy, demonstrating its protective efficacy. Additionally, the study medication was well-tolerated.

Details of the study results, including the actual numbers of subjects and data related to efficacy and safety, will be submitted to a scientific journal or academic society at a later date, and currently the dates for the publication and presentation of the comprehensive results have not been determined.

Daiichi Sankyo intends to apply for approval to manufacture and sell of Inavir in Japan for a prophylaxis indication by the end of 2012.

Date: August 22, 2012
Source: Daiichi Sankyo Company Ltd.


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE